Infant Bacterial Therapeutics Investor Relations Material
Latest events
Study Update
Infant Bacterial Therapeutics
Q1 2025
7 May, 2025
Q4 2024
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Infant Bacterial Therapeutics
Access all reports
Infant Bacterial Therapeutics is a Sweden-based pharmaceutical company focused on developing microbiome-based treatments for diseases affecting premature infants and children. Its primary focus is on preventing necrotizing enterocolitis and other serious conditions using live bacterial therapies. Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the NASDAQ Stockholm.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IBT
Country
🇸🇪 Sweden